Navigation Links
KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue

Martinsried, Germany, October 01, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it added KinAffinity to its service portfolio. KinAffinity provides invaluable information about a kinase inhibitors selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the limitations of traditional biochemical assays that only use recombinant proteins.

Kinase inhibitors with favorable pharmaceutical properties are extensively pursued as therapeutics in numerous oncological, neurological and inflammatory indications. However, their development faces significant challenges such as target specificity for the disease-relevant target proteins. Here, KinAffinity provides critical information to select the right lead compound for clinical development.

KinAffinity combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry (see Sharma et al., Nature Methods 2009). Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and competed with the kinase inhibitor of interest. Subsequently, bioinformatic methods are used to reveal the inhibitors quantitative cellular target profile. The inhibitors targets are ranked by their affinities and reported to the customer.

KinAffinity is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.


KINAXO Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, we closely cooperate with several of the Institutes most outstanding scientists in the field of chemical proteomics and quantitative mass spectrometry, namely Dr. Henrik Daub, Prof. Jesper Olsen and Dr. Jrgen Cox. KINAXOs technology portfolio delivers direct insights into a compounds cellular interactions and its mode of action and is routinely applied to decrease drug development times and improve therapeutic strategies. To expand its KinAffinity platform, KINAXO recently received financial funding from the Bavarian Ministry of Economics. The underlying technology was licensed from the Max Planck Society and co-developed by scientists of the Max Planck Institute of Biochemistry and KINAXOs scientists.
KINAXO has several ongoing collaborations with major pharmaceutical and biotechnology companies such as Boehringer Ingelheim, Johnson & Johnson and Bayer, and is financed by European investors BioM, High-Tech Grnderfonds, KfW, the Max Planck Society, and Mountain Partners.


Dr. Jutta Fritz
Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried, Germany
Phone +49 89 4613363-22

b3c newswire

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. Springer launches SpringerImages
3. ESHRE launches international study of polar body screening
4. Nutricia launches Nutra Neocate, weaning product designed for cows’ milk protein allergy
5. Swiss Initiative in Systems Biology launches new projects
6. Springer launches
7. Springer launches
8. UC Davis launches One Health care for wild mountain gorillas and human neighbors
9. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
10. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
11. Iowa State chemist synthesizes carbohydrates, launches startup company
Post Your Comments:
(Date:9/28/2015)... FRANCISCO , September 28, 2015 ... is expected to reach USD 12.03 billion by 2020, ... 2020. Technological advancements such as Backside Illumination (BSI) technique ... growth over the forecast period.      (Logo: ... back of the chip to reduce loss and, thus, ...
(Date:9/26/2015)...  Results of a TactioRPM pilot project in ... the Stanford Medicine X Conference. In a presentation ... Health Devices and Pharmacogenomics", Roger Simard , ... how senior patients equipped with connected health devices ... the TactioRPM remote patient monitoring platform were empowered ...
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... the Company has been dismissed by the court.  ... stated, "As we suspected, this case was brought by ...
(Date:10/12/2015)... , Oct. 12, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... company engaged in developing and commercializing novel treatments in ... of Dennis Turpin , the Company,s former Senior ... close its Quebec City office.  ... and Chief Executive Officer of the Company commented, "After ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl ... has joined the firm as a Premier Expert consultant. NDA Partners Premier ... bring extraordinary value to the company's clients. Premier Experts collaborate to design ...
(Date:10/10/2015)... 10. Oktober, 2015 Am 8. Oktober ... Demokratischen Partei für Kalifornien) ihre Würdigung der International ... in die Aufzeichnungen des Kongresses eintragen lassen. Die ... Association (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre ... des Bewusstseins über Plasmaspenden weltweit , Würdigung ...
Breaking Biology Technology: